OHR Pharmaceutical Inc (OHRP) Sees Significant Increase in Short Interest

OHR Pharmaceutical Inc (NASDAQ:OHRP) saw a large increase in short interest in the month of January. As of January 12th, there was short interest totalling 3,075,035 shares, an increase of 47.8% from the December 29th total of 2,080,161 shares. Approximately 5.7% of the shares of the company are short sold. Based on an average daily trading volume, of 7,535,665 shares, the short-interest ratio is currently 0.4 days.

Several institutional investors and hedge funds have recently added to or reduced their stakes in OHRP. Wedbush Securities Inc. bought a new stake in shares of OHR Pharmaceutical during the third quarter valued at approximately $311,000. Garrison Bradford & Associates Inc. increased its position in shares of OHR Pharmaceutical by 482.4% during the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 412,000 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of OHR Pharmaceutical by 0.7% during the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 5,481 shares during the period. Institutional investors and hedge funds own 8.24% of the company’s stock.

Shares of OHR Pharmaceutical (NASDAQ:OHRP) opened at $0.32 on Wednesday. The stock has a market capitalization of $18.20, a P/E ratio of -0.54 and a beta of 0.48. OHR Pharmaceutical has a 1 year low of $0.31 and a 1 year high of $2.18.

OHR Pharmaceutical (NASDAQ:OHRP) last released its quarterly earnings data on Friday, December 15th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08).

Several research analysts have commented on OHRP shares. Zacks Investment Research downgraded OHR Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Roth Capital started coverage on OHR Pharmaceutical in a research report on Monday, November 27th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, ValuEngine upgraded OHR Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.

COPYRIGHT VIOLATION WARNING: “OHR Pharmaceutical Inc (OHRP) Sees Significant Increase in Short Interest” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/31/ohr-pharmaceutical-inc-ohrp-sees-significant-increase-in-short-interest.html.

About OHR Pharmaceutical

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit